We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+18.8%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.68B
AUM Growth
+$421M
Cap. Flow
+$308M
Cap. Flow %
11.53%
Top 10 Hldgs %
68.02%
Holding
83
New
12
Increased
16
Reduced
6
Closed
11
Avg Time Held Equity + Options
0.7 years
Top 10 Avg Time Held Equity + Options
0.9 years
Top 20 Avg Time Held Equity + Options
1.1 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.9 years
Top 20 Avg Time Held Equity only
1.1 years

Top Buys

Rank Stock Value
1
ALEC icon
Alector
ALEC
+$68.6M
2
MORF icon
Morphic Holding, Inc. Common Stock
MORF
+$52.4M
3
RLAY icon
Relay Therapeutics
RLAY
+$34.9M
4
RCUS icon
Arcus Biosciences
RCUS
+$32.5M
5
JANX icon
Janux Therapeutics
JANX
+$31.4M

Top Sells

Rank Stock Value
1
ELDN icon
Eledon Pharmaceuticals
ELDN
+$11.9M
2
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
+$10.5M
3
NGNE icon
Neurogene
NGNE
+$8.45M
4
ACIU icon
AC Immune
ACIU
+$6.91M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$5.09M

Sector Composition

Rank Sector Weight
1 Healthcare 98.93%
2 Financials 0.6%
3 Miscellaneous 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BOLT icon
51
Bolt Biotherapeutics
BOLT
$7.71M
$2.32M 0.09%
7,500
– –
2021 Q1
1 quarter
BCAB icon
52
DELISTED
BIOATLA INC
BCAB
$2.12M 0.08%
1,000
– –
2020 Q4
2 quarters
BLSA
53
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$2.11M 0.08%
200,000
– –
2020 Q4
2 quarters
MLTX icon
54
MoonLake Immunotherapeutics
MLTX
$813M
$2.07M 0.08%
200,000
– –
2020 Q4
2 quarters
FVAM
55
DELISTED
5:01 Acquisition Corp
FVAM
$1.99M 0.07%
200,000
– –
2020 Q4
2 quarters
SRZN icon
56
Surrozen
SRZN
$276M
$1.99M 0.07%
+13,333
New +$1.98M
2021 Q2
0 quarters
EUCR
57
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
$1.97M 0.07%
200,000
– –
2021 Q1
1 quarter
FLAC
58
DELISTED
Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares
FLAC
$1.96M 0.07%
+200,495
New +$1.98M
2021 Q2
0 quarters
PMVP icon
59
PMV Pharmaceuticals
PMVP
$64.7M
$1.71M 0.06%
50,000
– –
2020 Q3
3 quarters
ARYD icon
60
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$1.61M 0.06%
150,000
– –
2021 Q1
1 quarter
RPTX icon
61
DELISTED
Repare Therapeutics
RPTX
$1.56M 0.06%
50,000
– –
2020 Q2
4 quarters
PRDS
62
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$1.5M 0.06%
150,000
– –
2021 Q1
1 quarter
MGTX icon
63
MeiraGTx Holdings
MGTX
$891M
$1.47M 0.05%
94,819
– –
2020 Q1
5 quarters
CMAXW icon
64
DELISTED
CareMax, Inc. Warrant
CMAXW
$1.29M 0.05%
100,000
– –
2020 Q4
2 quarters
TMPM
65
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$989K 0.04%
100,000
– –
2021 Q1
1 quarter
SRZNW icon
66
DELISTED
Surrozen Inc Warrant
SRZNW
$662K 0.02%
+66,665
New +$73K
2021 Q2
0 quarters
EUCRW
67
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
$656K 0.02%
66,666
– –
2021 Q1
1 quarter
FLACW
68
DELISTED
Frazier Lifesciences Acquisition Corporation Warrant
FLACW
$651K 0.02%
+66,665
New +$66.5K
2021 Q2
0 quarters
KNTE
69
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$582K 0.02%
25,000
– –
2020 Q4
2 quarters
OMEG
70
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$498K 0.02%
50,000
– –
2021 Q1
1 quarter
FSTX
71
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$395K 0.01%
46,000
– –
2021 Q1
1 quarter
TMPMW
72
DELISTED
Turmeric Acquisition Corp. Warrant
TMPMW
$330K 0.01%
33,333
– –
2021 Q1
1 quarter
ELDN icon
73
Eledon Pharmaceuticals
ELDN
$173M
– –
-1,115,721
Closed -$11.9M –
PRTA icon
74
CALL
Prothena Corp
PRTA
$429M
– –
-250,000
Closed -$6.28M –
WHWK icon
75
Whitehawk Therapeutics
WHWK
$165M
– –
-138,185
Closed -$2.67M –
1 2
3
4

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2021 Portfolio in Review

As of Q2 2021, EcoR1 Capital held 83 positions worth $2.68B, up 19% from $2.25B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

EcoR1 Capital deployed $308M of net new capital in Q2 2021, opening 12 new positions and adding to 16 existing holdings. Its largest new stake was Janux Therapeutics: 1,411,975 shares worth $35.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Neurogene, an estimated $8.45M trimmed.

  • EcoR1 Capital's largest Q2 2021 buy was Janux Therapeutics: 1,411,975 shares worth $35.2M.
  • EcoR1 Capital added most to Alector in Q2 2021, an estimated $68.6M increase.
  • EcoR1 Capital's biggest Q2 2021 reduction was Neurogene, cutting an estimated $8.45M.
  • EcoR1 Capital fully exited Eledon Pharmaceuticals in Q2 2021, selling an estimated $11.9M.
  • EcoR1 Capital's ten largest holdings make up 68% of its $2.68B portfolio in Q2 2021.
  • EcoR1 Capital opened 12 new positions and closed 11 in Q2 2021.
  • EcoR1 Capital's portfolio value rose 19% quarter-over-quarter to $2.68B.

Based on EcoR1 Capital's 13F filing for Q2 2021, filed 16 Aug 2021.